|7.05||-0.2800||-3.82%||Vol 1.42M||1Y Perf -43.40%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.30 4.26%|
|Target Price||16.64||Analyst Rating||Moderate Buy 2.18|
|Potential %||136.03||Finscreener Ranking||★★★+ 50.74|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 49.94|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 50.80|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||9.11||Earnings Rating||Strong Buy|
|Market Cap||575.51M||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||1st Nov 2023|
|Estimated EPS Next Report||-0.64|
|EPS Growth Next 5 Years %||13.80|
|Avg. Weekly Volume||2.67M|
|Avg. Monthly Volume||1.70M|
|Avg. Quarterly Volume||1.44M|
Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 7.05 per share at the end of the most recent trading day (a -3.82% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 575.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.
The one-year performance of Editas Medicine Inc. stock is -43.4%, while year-to-date (YTD) performance is -20.52%. EDIT stock has a five-year performance of -75.32%. Its 52-week range is between 6.33 and 14.23, which gives EDIT stock a 52-week price range ratio of 9.11%
Editas Medicine Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.49, a price-to-sale (PS) ratio of 42.90, a price to cashflow ratio of 616.40, a PEG ratio of -0.22, a ROA of -35.33%, a ROC of -39.15% and a ROE of -44.12%. The company’s profit margin is -87.89%, its EBITDA margin is -771.50%, and its revenue ttm is $13.18 Million , which makes it $0.19 revenue per share.
Of the last four earnings reports from Editas Medicine Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.64 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 01st Nov 2023.
The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.18), with a target price of $16.64, which is +136.03% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Editas Medicine Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.94, ATR14 : 0.48, CCI20 : -87.57, Chaikin Money Flow : -0.27, MACD : -0.41, Money Flow Index : 24.08, ROC : -12.63, RSI : 39.70, STOCH (14,3) : 28.37, STOCH RSI : 0.78, UO : 37.01, Williams %R : -71.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Bruce Eaton (Sold 4 536 shares of value $45 158 ), Eaton Bruce (Sold 4 765 shares of value $46 500 ), Mark S. Shearman (Sold 2 790 shares of value $26 966 ), Mei Baisong (Sold 4 317 shares of value $37 990 ), Michelle Robertson (Sold 6 416 shares of value $59 342 ), Robertson Michelle (Sold 7 172 shares of value $66 754 )
Thu, 28 Sep 2023 20:46 GMT Editas Medicine upgraded to Buy from Hold at Stifel- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.